510(k) Clearances – Robotics, AI and Diagnostics Lead the Watchlist
Overview
FDA issued 295 premarket notification clearance decisions during October of 2026 The records include 293 K-numbered submissions and two BK-numbered donor-testing submissions, all with decision dates from October 1 through October 30.
We screened the unique premarket notification records using device names, applicants, decision dates and initial indicators of potential significance. What we found is that October’s clearances illustrate the breadth of innovation occurring within the medical device industry, from sophisticated robotic platforms to specialized diagnostic assays and software-driven clinical tools. Click here to download the 2026 PMN clearance records.
They also demonstrate an important feature of the 510(k) pathway. Manufacturers can introduce new technologies, device modifications and expanded indications by demonstrating substantial equivalence to appropriate legally marketed predicate devices.
Robotic-assisted surgery continues to expand
Robotic platforms are evolving through additional indications. Two clearances for robotic platforms demonstrate how manufacturers can update established technologies to support additional clinical procedures. These submissions also emphasize the importance of validating new intended uses rather than assuming that previous clearance covers every application.
CMR Surgical – Versius Plus Surgical System (K261252)
FDA cleared CMR Surgical’s Versius Plus system on October 21 for specified benign gynecological procedures, expanding the system’s authorized uses in the United States. The clearance covers procedures including hysterectomy, removal of ovaries or fallopian tubes, ovarian cystectomy and treatment of adhesions in eligible adults aged 22 and older.
The development illustrates how manufacturers can expand the clinical applications of established robotic platforms through additional regulatory submissions and supporting evidence.
Neocis – Yomi S Robotic System (K261321)
FDA cleared Neocis’s Yomi S robotic system on October 13. The company subsequently announced expanded clearance supporting the placement of pterygoid dental implants, a technically demanding procedure involving implants positioned deep in the posterior upper jaw.
The clearance highlights the growing role of robotic guidance in dental surgery and the importance of procedure-specific validation when manufacturers extend the indications of an existing platform.
Artificial intelligence in diagnostic imaging
AI-enabled software remains an important area of regulatory activity. The clearances of imaging software highlight the continuing need to evaluate algorithm performance, intended users, clinical workflows and the relationship between software outputs and clinician decision-making.
Avicenna.AI – CINA-Aneurysm and CINA-Aneurysm+ (K262062 and K262147)
Two October clearances involving Avicenna.AI’s CINA-Aneurysm software products attracted attention during our 510(k) clearance screening. These products are part of the expanding category of AI-enabled medical imaging software intended to support clinical review and interpretation.
Molecular diagnostics and infectious disease testing
Diagnostic innovation extends across multiple clinical specialties. October’s records include respiratory testing, molecular diagnostics, infectious disease detection and specialized laboratory technologies.
BioFire Diagnostics – BIOFIRE SPOTFIRE Vaginitis Panel (K262136)
BioFire’s SPOTFIRE Vaginitis Panel was cleared on October 21. The clearance is noteworthy within the broader movement toward molecular diagnostic platforms that can support testing for infectious conditions.
GenMark Diagnostics – cobas eplex Respiratory Pathogen Panel 3 (K262938)
Cleared on October 30, this clearance illustrates that respiratory pathogen testing remains an important area of diagnostic development, particularly where laboratories must identify infectious agents efficiently to support patient management.
Public health and specialized clinical technologies
Centers for Disease Control and Prevention – B. anthracis Real-time PCR Assay (K262368)
The CDC’s molecular assay associated with Bacillus anthracis (the bacterium responsible for anthrax) was cleared on October 7. The submission is of particular interest from a public-health preparedness perspective.
Fertilis – microICSI Device (K262090)
Fertilis’s microICSI device, used in the field of assisted reproduction, was cleared on October 9. The submission illustrates continued device development in specialized reproductive medicine, where design and performance characteristics can be important to laboratory workflows.
Conclusion
October’s 510(k) clearances reflect an industry in which innovation is occurring across a wide range of medical technologies, from robotic-assisted procedures and artificial intelligence to molecular diagnostics and specialized clinical applications.
While not every clearance represents a major technological breakthrough, collectively they demonstrate how manufacturers continue to develop and refine devices to address evolving clinical needs.
For regulatory professionals, these developments reinforce the importance of evaluating not only what a device does, but also its intended use, supporting evidence, and the regulatory requirements that accompany its introduction into clinical practice.
FDA Approves Versatile Antibiotic Zevtera for Three Key Infections
FDA Approves Versatile Antibiotic Zevtera for Three Key Infections The U.S. Food and Drug Administration (FDA) announced today that the fight against bacterial infections has gained a significant boost with the recent approval of Zevtera (ceftobiprole medocaril sodium...
FDA Approves Treatment for Platinum-Resistant Ovarian Cancer
In a significant development for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, on March 22, 2024 the Food and Drug Administration (FDA) granted approval for mirvetuximab soravtansine-gynx, marketed as Elahere by...
FDA Approves Thoracic Stent Graft System
FDA Approves RelayPro Thoracic Stent Graft System for Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers Treatment The United States Food and Drug Administration (FDA) on March 7, 2023 approved the RelayPro Thoracic Stent Graft System, a new medical...
Prodigy Proclaim Spinal Cord Stimulation Systems
Significant advancement for chronic pain treatment On February 15, 2023, the U.S. Food and Drug Administration (FDA) announced the approval of the Prodigy Proclaim and Proclaim XR Spinal Cord Stimulation (SCS) systems. This approval marks a significant step forward in...
FDA Breakthrough Devices Program
FDA Breakthrough Devices Program The U.S. Food and Drug Administration (FDA) has established the Breakthrough Devices Program, a voluntary program that aims to expedite the development, assessment, and review of medical devices that demonstrate potential to provide...
Approvals for FDA Breakthrough Devices
Innovative Devices for Unmet Needs The Food and Drug Administration (FDA) has made a positive decision on the marketing applications of the following products. What sets them apart? They are innovative devices that qualified and participated in FDA's Breakthough...
A Team-based Approach to an Expedited 510(k)
Getting an expedited 510(k) submission So, you have created a new medical device by following your quality system’s design controls to plan the project, define design inputs, test to verify that outputs meet inputs, and validated your production product. Now what?...
FDA Approves Lamzede for Treatment of Alpha-mannosidosis
The U.S. Food and Drug Administration (FDA) on February 17, 2023 announced the approval the first-ever enzyme replacement therapy (ERT) for the treatment of rare alpha-mannosidosis, a genetic disorder that affects an individual's ability to break down complex sugars....
FDA Approves Rukabia for HIV Treatment
The U.S. Food and Drug Administration (FDA) on December 22, 2022 announced the approval of a new HIV drug called Rukobia (fostemsavir) for adults living with HIV who have limited treatment options. This drug is the first in a new class of HIV medications known as...
FDA Approval for Cancer Treatment Aid
The Food and Drug Administration (FDA) on 12 December 2022 announced the approval of Agilent's Resolution CTDX FIRST, a new in vitro diagnostic (IVD) medical device for use in the detecting a specific mutation in the KRAS gene in circulating cell-free DNA. This test...
